an equal and opposite reaction
Case Details for "Schering-Plough Corp. and Merck & Co. Inc."
Schering-Plough Corp. and Merck & Co. Inc. Settle Vytorin/Zetia Class Actions
Schering-Plough Corp. and Merck & Co. Inc. agreed to pay $41.5 million to settle class action litigation surrounding Vytorin/Zetia.
On Jan. 14, 2008, Schering-Plough Corp. and Merck & Co. Inc. released the ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) study, which found that Vytorin, a combination of Zetia and Zocor anti-cholesterol drugs made by the respective companies, was not more effective than less-costly generic Zocor.
The plaintiffs allege that the defendants engaged in unfair, unlawful or fraudulent business practices by failing to disclose the ENHANCE results for nearly two years.
The settlement includes a master class of all people and entities that purchased Vytorin or Zetia from Nov. 1, 2002, to Sept. 17, 2009. The master class is separated into consumer and third-party payer subclasses.
Posted on:2009-10-02
Company: Schering-Plough Corp. and Merck & Co. Inc.
Class:
Scope: Nationwide
Type of Case: Consumer
Settlement Administrator:
Contact Us Regarding This Settlement:
